Answers are grounded in this paper and cite their sources.
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy with limited durable treatment options despite evolving multimodal and systemic strategies. Systemic inflammation has emerged as a clinically relevant determinant of outcomes in several cancers. The systemic immune-inflammation index (SII; platelet count x neutrophil count / lymphocyte count) integrates key circulating immune cell populations and may serve as an accessible prognostic biomarker in PDAC. METHODS: statistic. Small-study effects were evaluated by funnel plot inspection and Egger's regression test. Funnel plot inspection did not suggest major asymmetry, and Egger's test did not provide statistical evidence of small-study effects (p = 0.072). CONCLUSIONS: Elevated SII is associated with poorer overall survival and represents a practical prognostic biomarker derived from routine laboratory testing. Considerable heterogeneity across studies-likely driven by differences in case mix, treatment context, and SII cutoff definitions-underscores the need for standardized thresholds and prospective, harmonized validation studies.
No takes yet. Share an insight, caveat, or question.
Pachinger-Molnár et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: